GlaxoSmithKline Upgraded to "Neutral" at JP Morgan (GSK)

GlaxoSmithKline Upgraded to “Neutral” at JP Morgan (GSK)


JP Morgan reported on Wednesday that it has upgraded healthcare company GlaxoSmithKline plc (GSK).

The firm has raised its rating on GSK to “Neutral” as analysts see upcoming catalysts balancing out risk.

GlaxoSmithKline shares were up 29 cents, or 0.56%, during pre-market trading Wednesday. The stock is up 20% YTD.

The Bottom Line

Shares of GlaxoSmithKline plc (GSK) have a 4.25% yield based on Tuesday’s closing price of $52.01.

GlaxoSmithKline plc (GSK) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today